Bangladesh Ziska Pharmaceuticals Lorlatinib/Lolatinib contraindications

Lorlatinib is an oral tablet that is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body. Lorlatinib belongs to the kinase inhibitor class of drugs. It works by blocking the activity of abnormal proteins that are signals for cancer cells to reproduce, which helps prevent or slow the spread of cancer cells. Bangladesh Ziska Pharmaceuticals Lorlatinib What are the contraindications for taking Lorlatinib?

Concomitant use of lorlatinib(Lorlatinib)with strong CYP3A inducers may decrease lorlatinib plasma concentrations, which may reduce LORBRENA’s efficacy. Severe hepatotoxicity occurred in healthy subjects treated with LORBRENA in combination with rifampicin (a strong inducer of CYP3A). Of 12 healthy subjects who received a single dose of 100 mg LORBRENA and multiple daily doses of rifampicin, 83% developed ALT or AST. Grade 3 or Grade 4 elevation, and 8% of subjects had grade ALT or AST 2 grade. One possible mechanism of hepatotoxicity is activation of the pregnane Xreceptor (PXR) by lobrena and rifampicin, both of which are PXR agonists. Lorlatinib is contraindicated in patients taking strong CYP3A inducers. Discontinue strong CYP3A inducers for 3 plasma half-lives before initiating lorlatinib.

Coadministration of lorlatinibwith moderateCYP3Ainducers may decreaselorlatinib plasma concentrations, which may reducelorlatinib's efficacy. Avoid moderateCYP3Ainducers withLORBRENAUse simultaneously. If concomitant use is unavoidable, increase the dose of lorlatinib.

Concomitant use of strongCYP3Ainhibitors may increase the plasma concentration of lorlatinib, which may increase the incidence and severity oflorlatinib adverse effects. Avoid the concomitant use of LORBRENA and strong CYP3A inhibitors. If concomitant use cannot be avoided, reduce the dose of lorlatinib.

Concomitant use of lorlatinib with fluconazole may increase the plasma concentrations of lorlatinib , which may increase the incidence and severity of lorlatinib adverse reactions. Avoid coadministration of lorlatinib and fluconazole. If concomitant use cannot be avoided, reduce the dose of lorlatinib.

LORBRENAis a moderateCYP3Ainducer and concomitant use of lorlatinibwill decrease the concentrations ofCYP3A substrates which may reduce the efficacy of these substrates. Avoid coadministration of LORBRENA with certain CYP3A substrates as minimal concentration changes may result in serious treatment failure. If concurrent use is unavoidable, increase the CYP3A substrate dose according to approved product labeling.

LORBRENAis a moderateP-gp inducer. Concomitant use oflorlatinibwill decreaseP-gpsubstrate concentrations which may reduce the efficacy of these substrates. Avoid coadministration of LORBRENA with certain P-gp substrates as minimal concentration changes may result in serious treatment failure. If concurrent use is unavoidable, increase the P-gp substrate dose according to approved product labeling. The current retail price of generic drugs from 100mg30pills3 is about one thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about overseas high-quality drugs for you.

xa0

xa0

xa0